- Home
- QDEL vs XOMAP Comparison
QDEL vs XOMAP Comparison
Compare QDEL & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QDEL
- XOMAP
- Stock Information
- Founded
- QDEL 1979
- XOMAP N/A
- Country
- QDEL United States
- XOMAP United States
- Employees
- QDEL N/A
- XOMAP 13
- Industry
- QDEL Medical Specialities
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- QDEL Health Care
- XOMAP Health Care
- Exchange
- QDEL Nasdaq
- XOMAP Nasdaq
- Market Cap
- QDEL N/A
- XOMAP N/A
- IPO Year
- QDEL N/A
- XOMAP N/A
- Fundamental
- Price
- QDEL $35.60
- XOMAP $25.60
- Analyst Decision
- QDEL Buy
- XOMAP
- Analyst Count
- QDEL 5
- XOMAP 0
- Target Price
- QDEL $51.20
- XOMAP N/A
- AVG Volume (30 Days)
- QDEL 821.4K
- XOMAP N/A
- Earning Date
- QDEL 05-07-2025
- XOMAP N/A
- Dividend Yield
- QDEL N/A
- XOMAP N/A
- EPS Growth
- QDEL N/A
- XOMAP N/A
- EPS
- QDEL N/A
- XOMAP N/A
- Revenue
- QDEL $2,782,900,000.00
- XOMAP N/A
- Revenue This Year
- QDEL $2.55
- XOMAP N/A
- Revenue Next Year
- QDEL $4.34
- XOMAP N/A
- P/E Ratio
- QDEL N/A
- XOMAP N/A
- Revenue Growth
- QDEL N/A
- XOMAP N/A
- 52 Week Low
- QDEL $29.74
- XOMAP N/A
- 52 Week High
- QDEL $49.45
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- QDEL 30.77
- XOMAP 45.97
- Support Level
- QDEL $38.49
- XOMAP $25.54
- Resistance Level
- QDEL $41.40
- XOMAP $25.83
- Average True Range (ATR)
- QDEL 1.65
- XOMAP 0.04
- MACD
- QDEL -0.37
- XOMAP -0.02
- Stochastic Oscillator
- QDEL 4.62
- XOMAP 20.62
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.